News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ceptaris Therapeutics, Inc. Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel


1/18/2012 6:52:10 AM

MALVERN, Pa.--(BUSINESS WIRE)--Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Ceptaris’ investigational drug, chlormethine gel (also known as mechlorethamine gel in the US), for the treatment of Cutaneous T-Cell Lymphoma (CTCL).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES